JP2016525563A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525563A5
JP2016525563A5 JP2016530548A JP2016530548A JP2016525563A5 JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5 JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
therapeutic agent
halogen atom
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016530548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525563A (ja
JP6453877B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/066629 external-priority patent/WO2015014998A1/en
Publication of JP2016525563A publication Critical patent/JP2016525563A/ja
Publication of JP2016525563A5 publication Critical patent/JP2016525563A5/ja
Application granted granted Critical
Publication of JP6453877B2 publication Critical patent/JP6453877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016530548A 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤 Expired - Fee Related JP6453877B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361861291P 2013-08-01 2013-08-01
US61/861,291 2013-08-01
US201361863118P 2013-08-07 2013-08-07
US61/863,118 2013-08-07
PCT/EP2014/066629 WO2015014998A1 (en) 2013-08-01 2014-08-01 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Publications (3)

Publication Number Publication Date
JP2016525563A JP2016525563A (ja) 2016-08-25
JP2016525563A5 true JP2016525563A5 (enExample) 2017-09-14
JP6453877B2 JP6453877B2 (ja) 2019-01-16

Family

ID=51260882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530548A Expired - Fee Related JP6453877B2 (ja) 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤

Country Status (6)

Country Link
US (1) US9795612B2 (enExample)
EP (1) EP3027194A1 (enExample)
JP (1) JP6453877B2 (enExample)
KR (1) KR20160036591A (enExample)
CN (1) CN106029077A (enExample)
WO (1) WO2015014998A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757385B2 (en) * 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
CA2947601A1 (en) * 2014-05-02 2015-11-05 Oncoethix Gmbh Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
CN107427524A (zh) * 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
US20180098997A1 (en) * 2015-04-03 2018-04-12 Oncoethix Gmbh Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
EP3658123A4 (en) * 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
BR112023025562A2 (pt) 2021-06-08 2024-02-20 Poseidon Innovation Llc Compostos anticâncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716490B2 (en) * 1996-09-13 2000-02-24 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compounds and pharmaceutical use thereof
CA2412776C (en) * 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
AU2006270187A1 (en) * 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
JP2010517510A (ja) * 2007-01-09 2010-05-27 ブリストル−マイヤーズ スクイブ カンパニー 前立腺細胞中のタンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用しかつ/またはそれを調節する化合物の活性を予測するためのポリヌクレオチドの同定
JP5478262B2 (ja) * 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
KR101805754B1 (ko) * 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
EP2569434B1 (en) 2010-05-14 2019-09-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia and related disorders
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
CA2877434A1 (en) * 2012-06-25 2014-01-03 Oncoethix Sa Method of treating lymphoma using thienotriazolodiazepine compounds
BR112015006537A2 (pt) 2012-09-28 2017-07-04 Oncoethix Sa dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico
US9757385B2 (en) * 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds

Similar Documents

Publication Publication Date Title
JP2016525563A5 (enExample)
JP2015531747A5 (enExample)
JP2016529246A5 (enExample)
JP2016538310A5 (enExample)
JP2017517579A5 (enExample)
RU2015101106A (ru) Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения
JP2016523270A5 (enExample)
JP2016507581A5 (enExample)
RU2015133528A (ru) Замещенные полициклические пиразольные ингибиторы киназной активности и их применение
JP2013540712A5 (enExample)
JP2021501208A5 (enExample)
JP2010241830A5 (enExample)
JP2014518544A5 (enExample)
JP2011527667A5 (enExample)
JP2014514317A5 (enExample)
HRP20201985T1 (hr) Piridonski spoj kao c-met inhibitor
JP2017529332A5 (enExample)
JP2015509536A5 (enExample)
JP2016501185A5 (enExample)
JP2019512535A5 (enExample)
JP2016531868A5 (enExample)
JP2017519727A5 (enExample)
JP2015504091A5 (enExample)
JP2017514909A5 (enExample)
JP2015537017A5 (enExample)